Star Ratings, Decentralized Trials, and Gene Therapy Frameworks

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning. The convergence of regulatory shifts and evidence evolution is particularly compelling right now.

MarcusSame here. We're looking at CMS Medicare Advantage Star Ratings Methodology Shift — which could fundamentally change how plans are evaluated. Then FDA Draft Guidance on Decentralized Clinical Trials — a major step for trial design. And ICER New Framework for Gene Therapies in Rare Diseases — a big shift in value assessment for these high-cost treatments.

SaraThat second one about decentralized trials is interesting to me — the operational implications for HEOR evidence generation are significant, and I wonder how payers will adjust their data requirements.

MarcusExactly. Let's get into it.

MarcusCMS has announced a significant shift in the Medicare Advantage Star Ratings methodology, focusing more on patient experience and outcomes rather than process measures. This could have major implications for how plans structure their benefits and provider networks.

SaraThat's one read — but I'd frame it slightly differently. The emphasis on patient experience metrics, like the CAHPS survey, might actually lead to more gaming of the system. We've seen that before with other quality measures.

MarcusThat's a fair point. CMS is trying to address that by weighting patient experience more heavily, but the risk of manipulation is real. What strikes me is the potential for this to drive plans to invest more in social determinants of health interventions to boost scores.

SaraRight, and from the payer side, that's a budget impact question. If plans are spending more on SDOH to improve stars, that could increase premiums without necessarily improving outcomes. The part that gives me pause is the timing — with the IRA putting pressure on Part D, this shift could exacerbate cost pressures.

MarcusI wonder if that's the full picture though. CMS is also incorporating more real-world data to verify these measures, which might mitigate gaming. But historically, when new metrics are introduced, there's a period of adjustment and unintended consequences.

SaraHistorical precedent is important here. Remember when HEDIS added the CAHPS measure? Plans initially saw their scores drop, then they adjusted. But the cost of improving those scores was passed on to beneficiaries. I'm concerned we'll see a repeat.

MarcusThat's a valid concern. However, the stakes are higher now because Medicare Advantage enrollment has exploded. If CMS doesn't get this right, it could undermine the entire program's value proposition. But I also think the move toward outcomes is long overdue.

SaraAgreed, but the devil is in the implementation. The methodology shift is coming at a time when plans are already navigating the IRA's drug negotiation provisions. This could create a perfect storm of complexity.

SaraThe FDA has released a draft guidance on decentralized clinical trials, emphasizing the use of telehealth, remote monitoring, and local labs. This is a significant step toward making trials more accessible and efficient, especially for rare diseases.

MarcusThat's one read — I'd frame it slightly differently. The guidance is a recognition that traditional trial sites are a major barrier to participation, but it doesn't fully address the regulatory challenges of using real-world data endpoints. The part that gives me pause is the lack of clarity on how sponsors will integrate decentralized elements without compromising data integrity.

SaraThat's fair. The FDA is pushing for innovation, but the guidance is still in draft form. What strikes me is the potential for this to accelerate evidence generation for rare diseases, where patient recruitment is a huge bottleneck. If done right, this could be transformative.

MarcusAbsolutely. But I keep coming back to the HEOR implications. If trials are decentralized, we'll need new methods for health economic modeling, especially for cost-effectiveness. The traditional approach of using RCT data might not hold when the trial population is more representative but the data is more heterogeneous.

SaraExactly. And from the payer side, the question is whether decentralized trials will produce robust enough evidence for coverage decisions. We've seen issues with real-world data in the past, especially in oncology. The FDA's guidance doesn't guarantee that the data will be HTA-ready.

MarcusThat's a critical point. The guidance is a step forward, but it doesn't solve the evidence generation puzzle for rare diseases. Sponsors will need to invest heavily in HEOR alongside the trial design. This is one of those stories where the potential is huge, but the operational challenges are significant.

SaraAgreed. I'll be watching how CMS and other payers react to data from decentralized trials. If they don't trust it, the whole effort could be for naught.

MarcusICER has unveiled a new framework for evaluating gene therapies in rare diseases, incorporating a multi-criteria decision analysis approach. This is a direct response to the unique challenges of these treatments, including high costs and long-term uncertainties.

SaraThat's one read — but I'd push back slightly. While MCDA is a step in the right direction, it doesn't address the fundamental issue of budget impact. ICER's cost-effectiveness thresholds are still based on traditional metrics, which don't capture the one-time cure model. The part that gives me pause is the lack of clarity on how this will translate into real-world pricing negotiations.

MarcusThat's a fair point. ICER is trying to balance innovation with affordability, but the framework doesn't solve the budget impact problem. What strikes me is the emphasis on patient input in the MCDA, which is a positive step. But I wonder if it will be enough to convince payers to accept these prices.

SaraRight, and from the payer side, the opportunity cost is enormous. If a gene therapy costs $2 million, that's money not spent on other treatments. ICER's framework doesn't provide a mechanism to manage that trade-off. This is one of those stories where the theory is sound, but the practical application is still unclear.

MarcusI agree. The framework is a starting point, but it doesn't address the structural issues in healthcare financing. We need new models, like outcomes-based agreements, to make these treatments sustainable. But ICER's move is still significant because it acknowledges the limitations of traditional cost-effectiveness analysis.

SaraAgreed. I'll be watching how payers in Europe and the US react to this framework. If it leads to more consistent value assessments, that could be a game-changer. But if it's just another layer of complexity, it might not move the needle.

SaraNICE has updated its guidance on using real-world evidence in technology appraisals, now allowing RWE to supplement or even replace RCT data in certain cases. This is a major shift for the UK, which has traditionally been RCT-centric.

MarcusThat's one read — I'd frame it slightly differently. The guidance is a recognition of the practical challenges in conducting RCTs, especially for rare diseases and innovative technologies. But the part that gives me pause is the risk of bias in RWE. NICE has put in place safeguards, but the potential for confounding is still high.

SaraThat's fair. The guidance does emphasize the need for robust RWE, but the reality is that generating high-quality RWE is resource-intensive. What strikes me is the global implications. If NICE accepts RWE more readily, other HTA bodies might follow, which could accelerate access but also increase uncertainty.

MarcusExactly. And from the industry perspective, this is a double-edged sword. On one hand, it could make it easier to get drugs approved and reimbursed. On the other, it opens the door to more stringent HTA reviews based on real-world data, which might not always be favorable. This is one of those stories where the potential for faster access is balanced by the risk of unpredictable outcomes.

SaraAgreed. I'll be watching how this plays out in practice. If NICE starts using RWE more, we might see a shift in how companies design their evidence strategies. But the key question is whether RWE can truly replace RCTs for decision-making.

MarcusThat's the million-dollar question. My sense is that RWE will supplement, not replace, RCTs for now. But the updated guidance is a clear signal that HTA is evolving with the times.

SaraA lot to think about today. I'll be watching how CMS's Star Ratings shift impacts plan behavior and beneficiary costs.

MarcusSame — and for me the thread running through today is the tension between innovation and sustainability. Whether it's decentralized trials, gene therapies, or RWE, we're seeing a push for more flexible evidence generation, but the system's ability to absorb that is still in question.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.